Inhibition of Angiotensin-Converting Enzyme in Renal-Transplant Recipients with Hypertension

HYPERTENSION has a high prevalence among recipients of renal allografts.1 , 2 Such post-transplantation hypertension may contribute3 , 4 to the high mortality from atherosclerotic vascular disease observed in this relatively young population.5 , 6 Although the cause of persistent post-transplantation hypertension is not well understood, it is believed to be multifactorial in nature,7 , 8 and several investigators have suggested that the renin–angiotensin system plays an important part.9 , 10 Captopril, an oral angiotensin-converting-enzyme inhibitor, has been reported to be an especially effective agent for hypertensive states mediated by the renin–angiotensin system.11 , 12 In cases in which the renin–angiotensin system is important in post-transplantation hypertension, captopril should be an ideal . . .